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Abstract
Health effects following low doses of ionizing radiation are uncertain. Military veterans at the 
Nevada Test Site (NTS) during the SMOKY atmospheric nuclear weapons test in 1957 were 
reported to be at increased risk for leukemia in 1979, but this increase was not evaluated with 
respect to radiation dose. The SMOKY test was one of 30 tests in 1957 within the PLUMBBOB 
test series. These early studies led to public laws where atomic veterans could qualify for 
compensation for presumptive radiogenic diseases.
A retrospective cohort study was conducted of 12,219 veterans at PLUMBBOB test series, 
including 3,020 at the SMOKY nuclear test. Mortality follow-up was through 2010 and observed 
causes of death were compared with expected causes based on general population rates. Radiation 
dose to red bone marrow was based on individual dose reconstructions, and Cox proportional 
hazards models were used to evaluate dose response for all leukemias other than chronic 
lymphocytic leukemia (non-CLL leukemia).
Vital status was determined for 95.3% of the 12,219 veterans. The dose to red bone marrow was 
low (mean 3.2 mGy, maximum 500 mGy). Military participants at the PLUMBBOB nuclear test 
series remained relatively healthy after 53 years and died at a lower rate than the general 
population. In contrast, and in comparison with national rates, the SMOKY participants showed 
significant increases in all causes of death, respiratory cancer, leukemia, nephritis and nephrosis, 
and accidents, possibly related in part to lifestyle factors common to enlisted men who made up 
81% of the SMOKY cohort.
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Compared with national rates, a statistically significant excess of non-CLL leukemia was observed 
among SMOKY participants (Standardized Mortality Ratio=1.89, 95% 1.24–2.75, n=27) but not 
among PLUMBBOB participants after excluding SMOKY (SMR=0.87, 95% 0.64–1.51, n=47). 
Leukemia risk, initially reported to be significantly increased among SMOKY participants, 
remained elevated, but this risk diminished over time. Despite an intense dose reconstruction, the 
risk for leukemia was not found to increase with increasing levels of radiation dose to the red bone 
marrow. Based on a linear model, the estimated excess relative risk per mGy is −0.05 (95% CI 
−0.14, 0.04). An explanation for the observed excess of leukemia remains unresolved but 
conceivably could be related to chance due to small numbers, subtle biases in the study design 
and/or high tobacco use among enlisted men. Larger studies should elucidate further the possible 
relationship between fallout radiation, leukemia and cancer among atomic veterans.
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1. INTRODUCTION
Between 1945 and 1962, the United States conducted more than 230 atmospheric nuclear 
weapons tests primarily in Nevada and the Pacific Ocean. The detonation of a nuclear device 
was called a test and each test was given a name. An official grouping of nuclear weapons 
tests was called a test series. The 230 tests were grouped into 19 test series. On August 31, 
1957, a nuclear weapon named SMOKY was detonated at the Nevada Test Site (NTS). 
SMOKY was one of 30 tests comprising the Operation PLUMBBOB test series. Twenty-two 
years later, a team from the Centers for Disease Control and Prevention (CDC) published 
observations of a significant excess of eight leukemia incident cases among 3,224 military 
participants present at the NTS during this test, but incompletely identified [1]. Attempts 
were made to locate and contact these participants. A second and a third study reported 
results from an intensive follow-up that located 95.5% of all SMOKY cohort members and 
identified ten leukemia incident cases and eight leukemia deaths through 1979 [2,3]. This 
subsequent follow-up also documented the health status of the veterans and obtained, where 
appropriate, their medical records and death certificates. These studies and a later fourth 
study [4], confirmed the statistically significant increase in predominantly myeloid leukemia 
and non-significant increases in melanoma of the skin, cancers of the genital system, eye and 
orbit, brain and nervous system, and polycythemia vera. When these studies were 
undertaken, the radiation exposure data were often limited to a single film badge reading, 
which may not have represented the true or complete exposure to radiation from nuclear 
weapons tests or other sources of radiation [3,4].
The original publications had brought attention to the scientific and medical communities 
the importance of low dose radiation research, spurring on other studies and eventually 
leading to public laws where military veterans who served during nuclear weapons testing 
could qualify for compensation for presumptive radiogenic diseases [5,6]. Further, it raised 
issues regarding the carcinogenic effectiveness of low dose radiation that was received 
Caldwell et al. Page 2
J Radiol Prot. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
gradually over time and not during a brief moment in time. Such concerns remain important 
societal issues today as reflected in the Low-Dose Radiation Research Act of 2015 currently 
before the U.S. Senate [7].
The current study updates the mortality follow-up of the SMOKY cohort from 1979 to 2010, 
i.e., 53 years after the 1957 test. All participants at the PLUMBBOB test series, of which 
SMOKY was one of 30 tests, were also similarly followed. PLUMBBOB is one of the test 
series included in the ongoing Eight Series Study of cancer among atomic veterans 
conducted by Vanderbilt University in cooperation with the National Council on Radiation 
Protection and Measurements [8,9]. There have been several studies of atomic veterans that 
combined participants at different test series. The ongoing Eight Series Study is 
investigating participants at eight nuclear weapons test series: CROSSROADS, 
GREENHOUSE, UPSHOT-KNOTHOLE, CASTLE, REDWING, PLUMBBOB, 
HARDTACK I and TRINITY, and is named accordingly. The importance of this study 
relates to the effects of chronic radiation exposures rather than acute exposures as 
experienced by Japanese atomic bomb survivors.
2. METHODS
Human subjects research approval was received from Vanderbilt University and CDC 
Institutional Review Boards. Consent was obtained from participants of the SMOKY follow-
up study at the time of the original CDC studies and in accordance with protocol at the time.
2.1. Population identification
PLUMBBOB nuclear weapons test participants were identified using the Nuclear Test 
Review Program and Information System (NuTRIS) in cooperation with the Defense Threat 
Reduction Agency [10]. The NuTRIS database includes detailed information on unit 
attachment dates among military participants as well as film badge readings of individuals 
and representative veterans present at all nuclear test series. Participants of the Eight Series 
Study represented nearly half of all U.S. participants at above ground nuclear tests and 
included military personnel previously studied in an investigation of five series (which 
included the PLUMBBOB test series) and the CROSSROADS study conducted by the 
Medical Follow-up Agency [11–14].
The SMOKY cohort was identified by matching the original CDC population [2–4], to the 
Eight Series Study population on the first five matching criteria used by the National Death 
Index (based on the Social Security number, birth date, and name) [15]. Further probabilistic 
matching on key variables (last name, first name, birth year, and military service 
identification numbers) was done using the CDC LinkPlus probabilistic matching software 
[16]. We successfully matched 3,020 (94%) of the original 3,217 SMOKY test participants 
[2–4]. The small difference between the numbers in the original SMOKY study population 
and in the current study population resulted from changes in or the unavailability of 
identifying variables (Social Security Number, name, birthdate, and military service 
identification numbers).
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2.2. Tracing
Mortality status as of December 31, 2010 was obtained by matching the study population 
against the Social Security Administration death master file as well as numerous state 
mortality data files. For those who had not died but were presumed to be alive, vital status as 
living was confirmed through linkages with the Social Security Administration Service for 
Epidemiological Researchers that also included information from the Internal Revenue 
Service. Deaths and alive status were also obtained using the Department of Veterans Affairs 
Beneficiary Identification Record Location System, where matching on military service 
identification numbers was possible (especially helpful because Social Security number was 
not available for many participants). Cause of death was obtained from the National Death 
Index, state mortality data, previously conducted epidemiologic studies [11–14], or death 
certificates obtained from state departments of health, regional offices of the Department of 
Veterans Affairs and the Federal Archives. Contributing causes of death, in addition to the 
primary cause of death, were also available from the National Death Index and death 
certificates. Credit bureaus and LexisNexis were used to confirm and correct key matching 
variables. Overall, these techniques confirmed the vital status of 95.3% of the PLUMBBOB 
test series population of whom 62% had died (Figure 1). For about 3% of those known to 
have died, cause of death was not available. Deaths outside the United States, including 
those during military action, are excluded from the standardized mortality analyses because 
national mortality rates used for comparison are based only on persons who died inside the 
United States.
2.3. Radiation dose assessment
Radiation dose assessment during nuclear weapons testing was based on data from the 
NuTRIS database, which included film badge measurements, and on a substantial number of 
historical documents related to the atmospheric nuclear testing program compiled to support 
estimates of dose for compensation programs for exposed veterans [5]. In accord with the 
case-cohort study design, dose reconstructions and categorization was for all cases of 
leukemia and a random sample of all veterans in the Eight Series Study. The detailed dose 
reconstruction methodology for nuclear weapons test participants was reported by Till and 
colleagues [17].
Available dosimetry film badge records specified the dates of badge issue and badge return 
but did not specify the nuclear test/s covered by the badge. The badge exposure period often 
spanned the dates of more than one test in the PLUMBBOB test series (most tests were just 
a few days apart). Therefore, selecting film badge doses that included the date of the 
SMOKY test (August 31, 1957) yielded more military personnel than the number of 
SMOKY participants included in the CDC investigations. Our definition of SMOKY 
participants is taken as the cohort from the original CDC studies.
Several military units, such as helicopter and transportation units, participated in SMOKY 
and also in other tests conducted during August and September 1957. Many members of the 
SMOKY cohort were in support units at Camp Desert Rock and did not participate directly 
in any test activities or receive any meaningful exposure.
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For the radiation dose reconstructions for all leukemia deaths and the 1% random sample, 
radiation exposures that occurred at any of the 19 test series in which the veterans 
participated were included. To obtain as complete an assessment of occupational radiation 
exposure as possible, we also linked the rosters of atomic veterans with dosimetry registries 
available from the military services (Navy, Army, and Air Force), the U.S. Nuclear 
Regulatory Commission’s Radiation Exposure Information Reporting System, the U.S. 
Department of Energy’s Radiation Exposure Monitoring System, and a private dosimetry 
service (Landauer, Inc.). This supplemental linkage provided additional radiation exposure 
information for about 3 percent of the participants in the PLUMBBOB test series.
2.4. Statistical analysis
Standardized mortality ratios (SMR) analyses were conducted comparing the number of 
observed deaths with the number of expected deaths based on mortality rates in the general 
population using an approach similar to the University of Pittsburgh’s Occupational Cohort 
Mortality Analysis Program [18]. In brief, male population rates for specific causes of death 
by age and calendar year are applied to the corresponding person-years of follow-up to 
obtain the expected number of deaths had the veteran population experienced the same force 
of mortality as that of the general population. The start of follow-up is taken as the date of 
the first participation in the PLUMBBOB test series for PLUMBBOB test participants and 
the date of the SMOKY test (August 31, 1957) for the SMOKY test participants. The end of 
the follow-up is taken as the date of death, age 95, December 31, 2010, or whichever came 
first. The observed and expected numbers of deaths for selected causes were examined 
overall and by two time periods, 1957–1979 representing the follow-up period for the 
original SMOKY population [3], and 1980–2010 for the subsequent follow-up period. 
Statistical variability was evaluated by the 95% exact Poisson confidence interval (CI) of the 
SMR assuming that the observed number of deaths followed a Poisson distribution. A 95% 
CI that excludes 1.0 was considered as statistically significant at the 2-sided significance 
level of 0.05. Exact p-values are also presented when informative.
Because it would be prohibitively expensive to perform individual dose reconstructions on 
all test participants in the Eight Series Study, the case-cohort design was employed [19–22]. 
Cases are all test participants at the PLUMBBOB test series and the SMOKY test in whom 
leukemia developed, excluding chronic lymphocytic leukemia (CLL), which is not generally 
considered to be induced by radiation. The subcohort for comparison is a 1% random sample 
(n = 1,076) within defined strata from the overall cohort of 114,270 Eight Series Study 
participants. Rank (enlisted/officer) was considered a surrogate measure of socio-economic 
status (SES). Cox proportional hazards modeling was used to compute risks for non-CLL 
across categories of estimated radiation dose to the red bone marrow [23]. Adjustment was 
made for year of birth, year of first test participation, service and rank, and sampling fraction 
for the subcohort. To allow for a possible minimum latent period between radiation exposure 
and leukemia death, doses were lagged by 2 years, i.e., doses were excluded if they occurred 
2 years or less before the date of death. Age was used as the timescale, and R version 3.02 
was used for the analysis [24].
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A cohort comparison with the entire 114,270 atomic veterans in the Eight Series Studies was 
also conducted based on the NuTRIS doses. As above, film badge results and NTPR generic 
dose reconstructions for each military unit were available as a starting point for estimating 
both external and internal exposure and organ doses for all atomic veterans. Much of the 
detailed information available, i.e., the NuTRIS doses, had been compiled to support 
estimation of dose for compensation programs for exposed veterans [5, 6]. The subcohort of 
1,076 randomly selected participants formed the comparison group for which 
comprehensive dose reconstruction was performed for the case-cohort analyses [17]. During 
the dose reconstruction [17], it was found that the NuRIS dose [5], available for the entire 
cohort, could be adjusted with a scaling factor to bring them into close alignment with the 
dose estimates for organs where internal exposures from weapons fallout were negligible. 
The NuTRIS doses available for the entire cohort of atomic veterans are for external 
radiation and do not consider internal radiation, but since any intakes of radionuclides would 
contribute only a negligible dose to red bone marrow they would be of little consequence. 
These adjusted NuTRIS dose estimates are used in a full cohort analysis for comparison 
with the case-cohort analyses. Specifically, Cox proportional hazards modeling was used to 
compute risks of leukemia across categories of the adjusted NuTRIS dose estimates to the 
red bone marrow for the entire cohort of 114,270 veterans. Adjustment was made for year of 
birth, year of first test participation, test area and rank. Age was used as the timescale. All 
statistical analyses where conducted using R version 3.02 for both the Cox and linear models 
[24].
3. RESULTS
The Eight Series Study cohort consisted of 114,270 male veterans, of whom 12,219 
participated in the PLUMBBOB test series and 3,020 at the SMOKY test. Vital status as of 
December 31, 2010 was determined for 95.3% of all participants in the PLUMBBOB test 
series (Figure 1).
Compared with other PLUMBBOB participants, SMOKY participants were more likely to 
be Army personnel (99% vs. 44%), enlisted men (81% vs. 53%), 24 years of age or younger 
(57% vs. 39%), and to have participated in only one test series (98% vs. 88%) or to have 
received a radiation dose of < 5 mSv (71% vs. 64%) (Table 1).
For participants in the PLUMBBOB nuclear test series excluding the SMOKY cohort, the 
SMRs over all follow-up periods (1957–2010) for a number of causes were statistically 
significantly less than 1.0, including all causes of death, all heart disease, all malignant 
neoplasms, diabetes mellitus, cirrhosis of the liver, suicides, non-malignant respiratory and 
kidney diseases, and tuberculosis (Table 2).
In contrast, for participants at the SMOKY test, the SMRs over all follow-up periods (1957–
2010) were statistically significant greater than 1.0 for all causes of death (SMR = 1.06, 95% 
CI 1.02–1.11, p < 0.001), all malignant neoplasms (SMR = 1.14, 95% CI 1.05–1.25, p = 
0.002), respiratory cancer (SMR = 1.16, 95% CI 1.0–1.33, p = 0.038), leukemia other than 
CLL (SMR = 1.89, 95% CI 1.24–2.75, p < 0.001), non-malignant kidney disease (nephritis 
and nephrosis) (SMR = 1.53, 95% CI 1.03–2.19, p = 0.018), and accidents (SMR = 1.30, 
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95% CI 1.06–1.57, p = 0.007) (Table 2). The non-CLL leukemias were predominantly 
myeloid leukemia (67% in the first follow-up period and 61% in the second follow-up 
period). The excess of non-CLL leukemia was most apparent in the first follow-up period 
and then declined but persisted through 2010 (Figure 2).
The participants at SMOKY where younger than participants at the other tests in the 
PLUMBBOB series. Age at participation was evaluated to learn whether the excess 
leukemias among SMOKY participants might have been concentrated in the younger 
soldiers, but there was little statistical evidence of heterogeneity by age. The SMRs for 
leukemia other than CLL were 2.28 (n=3), 2.39 (n=13), 1.19 (n=3), and 1.60 (n=8) for ages 
at participation under 20 y, 20–24 y, 25–29 y, and over 30 y, respectively.
An intra-cohort dose-response evaluation (internal analysis) was performed among the 27 
non-CLL cases among the SMOKY participants and a comparison sample of 1,076 atomic 
veterans in the Eight Series cohort (Table 3). The 27 non-CLL cases were distributed over 
categories of dose to the red bone marrow, and increasing dose estimates did not increase 
risk for non-CLL. A cohort comparison with the entire 114,270 atomic veterans in the Eight 
Series Studies was also conducted based on the NuTRIS doses. A comparison between the 
NuTRIS doses and the subcohort doses (which were based on a comprehensive dose 
reconstruction) [17] showed a strong correlation with only a scaling factor of about 0.64 
needed to bring them into close alignment. The pattern of leukemia risk over categories of 
NuTRIS bone marrow dose is similar to that seen for the case-cohort analysis (Table 3). 
Based on a linear model, the estimated excess relative risk per mGy is −0.05 (95% CI −0.14 
to 0.04).
Similar dose-response evaluations for all PLUMBBOB participants also showed little 
evidence for a relationship between leukemia other than CLL and radiation dose estimates. 
Comparisons using different subcohorts (i.e., the Eight Series subcohort, the NTS subcohort 
and the PLUMBBOB subcohort) yielded essentially the same null results (data not 
presented).
4. DISCUSSION
The continued concern about the risks from low level radiation exposure remains today 
despite increased knowledge of radiation effects and continued efforts to minimize 
unnecessary radiation exposures in occupation, medical, and environmental circumstances 
[25]. Veterans and other populations exposed to radiation remain concerned about their 
potential risks and the specific health conditions that might be related to their past exposure.
This 53-year mortality follow-up of soldiers at one large Nevada nuclear test series and of an 
intensively studied cohort of soldiers present at one test (SMOKY) shows that mortality in 
the PLUMBBOB test series participants, other than those at SMOKY, is statistically 
significantly less than that expected from all causes of death and from specific grouped 
causes of death, including all heart disease, all malignant neoplasms, all non-malignant 
respiratory diseases, diabetes mellitus, liver cirrhosis, nephritis and nephrosis, suicide, and 
tuberculosis. The deficit particularly in heart disease deaths demonstrates the healthy warrior 
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effect due to selection of a healthier than normal population group for entry into and 
persistence during military service [26,27]. Interestingly, deaths due to heart disease were 
significantly reduced only during the first 22 years of follow-up but not later. The selection 
factors associated with the healthy worker effect, particularly for heart disease, often 
diminish significantly with time since initial selection for employment [28].
Follow-up studies of other participants at nuclear tests from Australia, New Zealand and the 
United Kingdom have reported increases in leukemia but not in relation to radiation dose, 
nor have there been consistent reports of increases in other malignancies [29–32]. 
Participants at the British nuclear tests also reflect the healthy warrior effect in that the SMR 
for all causes of death was significantly below 1.0 (SMR = 0.86) [30].
Compared with other occupationally-exposed populations the SMOKY cohort and the other 
veterans in the PLUMBBOB tests received relatively lower radiation exposures. 
Nonetheless, approximately 5% of participants received >50 mSv from all sources of 
identified occupational radiation exposure.
Besides estimating radiation doses to individuals, the dosimetry team investigated activities 
of the various military units in the SMOKY cohort to determine if any unusual maneuvers 
occurred that may have led to increased radiation dose or exposure to other environmental 
hazards. We could not find any particular activity or type of exposure unique to the SMOKY 
cohort. One activity known as Task Force Warrior [11], involved members of the SMOKY 
cohort taken closer to areas near the bomb test site. Three of these men were reported to 
have died from non-CLL leukemia [11]. While no film badge indication of excess radiation 
exposure was found [11], the increase in Task Force Warrior activities among cohort 
members in whom leukemia developed is noteworthy. Dosimetry uncertainty was also 
evaluated and the effect of shared Berkson (classical) error on inferences was determined to 
depend on both the strength of the dose response and the extent of sharing of dosimetry 
errors.32 Since the sharing of errors was negligible [17,33], accounting for uncertainty in the 
dose-response analyses also has a negligible effect.
As in our initial papers [2–4], and other studies that included SMOKY participants [11,12], 
we can only speculate why the SMOKY participants show increases in leukemia, certain 
cancers, and nonmalignant diseases. Given our dose reconstruction estimates and the 
absence of a dose response, we have little evidence that radiation is the cause. Furthermore, 
the absence of any such excesses in the other PLUMBBOB participants suggests that the 
SMOKY veterans had some characteristics, currently unknown, that increased their 
mortality risks, overall and for selected causes of death. Interestingly, the SMOKY 
participants differed from other atomic veterans (and the general population it seems) in 
surrogate measures of socio-economic status, e.g., more SMOKY participants were enlisted 
men (81% vs. 53%). Because enlisted men, similar to blue collar workers, are more likely to 
smoke cigarettes than officers or white collar workers, such differences might explain the 
elevations in lung cancer and nonmalignant kidney disease [34–37].
An intriguing finding in our study is the apparent absence of the healthy warrior effect in the 
SMOKY cohort, unlike that seen among other PLUMBBOB nuclear test participants. Again, 
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the increase in lung cancer and kidney disease suggests that smoking cigarettes might have 
been more prevalent in the SMOKY cohort with a larger percentage of enlisted personnel, 
and possibly related to the general availability of cigarettes in military rations during and 
after World War II and the Korean conflict [38]. The increase in accidental deaths also 
suggests that SMOKY cohort members may have been risk takers or employed in dangerous 
occupations. Since we compared many causes of death over two time periods, the leukemia 
excess in the SMOKY cohort, one of 30 tests during the PLUMBBOB test series, could be a 
chance finding. Finally, the possibility of an unusual and undetermined bias on how the 
SMOKY cohort was selected might also have been a factor.
The full cohort analysis of all 114,270 veterans in the Eight Series Study applied the 
adjusted NuTRIS doses and the cohort results were nearly identical with those from the 
case-cohort analysis. The NuTRIS doses were only for external exposures and did not take 
into account any internal intakes of radionuclides from weapons fallout. However, any 
intakes of radionuclides would contribute only a negligible dose to bone marrow and thus 
would be of little consequence for leukemia. The strong correlation had not been anticipated 
because the NuTRIS doses had been developed to be “high-sided” and for compensation 
purposes. One implication of these nearly identical results for leukemia is that many other 
cancers can now be evaluated inexpensively when it is unlikely that any internal intakes 
would contribute to organ dose. Specifically, the NuTRIS adjustment factor of 0.64 for red 
bone marrow doses can be scaled by the respective ratios of exposure-to-dose coefficients 
for gamma rays for male breast, testes, brain, heart and other organs to red bone marrow [39] 
to estimate the corresponding organ absorbed doses from external exposure.
Strengths of the study include the cohort design, the near complete follow-up and mortality 
ascertainment over a 53-year period, the comprehensive dose reconstructions and linkages 
with other dosimetry data bases to estimate cumulative radiation doses, and the access to 
unique military and veteran data bases that enhanced the quality and completeness of the 
data collected. Limitations include the low radiation doses received during the atmospheric 
weapons tests, the relatively small number of leukemia deaths, the inability to control 
directly for potential confounders such as smoking, and reliance on death information and 
not incidence. Over the years of study, however, myeloid leukemia was associated with a 
high fatality rate so that mortality would reflect incidence fairly closely. On the other hand, 
there have been recent improvements in survival for CML in the United States, approaching 
64% (http://seer.cancer.gov/statfacts/html/cmyl.html) so that persons who developed CML 
after 2000 would have been less likely to have died than in earlier years. We did search death 
notifications for contributing causes of death and found only one mention of CML, 
suggesting that there were few persons with CML who died of other causes. Further the 
study of atomic bomb survivors indicates a strong decline in the excess of CML over time 
and with attained age [40] suggesting that few radiation-related cases would have occurred 
in these later years. Nonetheless, a small number of cases of CML conceivably could have 
been missed and an incidence study would have had more statistical power to detect an 
excess had there been one.
Rank (enlisted/officer) was used as the measure of SES in the internal analyses as a 
surrogate control for smoking and other unknown factors. Cigarette smoking has been 
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associated with a relatively small risk of myelogenous leukemia among military veterans 
[41], but it is unlikely that large differences in smoking by dose categories exist that might 
distort the dose-response analyses, particularly after adjusting for SES. Conceivably, 
smoking might have contributed to the unexplained excess of leukemia deaths among 
SMOKY veterans.
The conundrum of the SMOKY cohort remains. The radiation dose reconstruction and 
environmental records do not indicate that SMOKY participants experienced greater or 
different radiation exposure than other test participants. Was the SMOKY cohort somehow 
different or less fit than participants at the other PLUMBBOB nuclear tests? Where SMOKY 
participants heavy smokers which contributed to their excess of lung cancer and conceivably 
of leukemia? Or is this cohort finding simply a chance observation? Nothing we have found 
so far suggests that radiation exposure in the SMOKY cohort differed from those in the other 
PLUMBBOB participants.
5. CONCLUSION
Military participants at the PLUMBBOB nuclear test series remained relatively healthy after 
53 years and continued to die at a lower rate than the general population. In contrast, the 
SMOKY cohort showed significant increases in all causes of death, respiratory cancer, 
nephritis and nephrosis, and accidents, possibly related to lifestyle factors common to 
enlisted men who made up 81% of the cohort. Leukemia risk, initially reported to be 
significantly increased among SMOKY participants, remained elevated, but this risk 
diminished over time. Despite an intense dose reconstruction, the risk for leukemia was not 
found to increase with increasing levels of radiation dose to the red bone marrow. 
Historically, the SMOKY studies have importance in recognizing that environmental 
exposure from atmospheric testing may have contributed to subsequent health effects, and 
Public Laws were enacted to compensate atomic veterans for their service. The larger Eight 
Series study of atomic veterans, which includes Plumbbob as one of the eight test series, 
should elucidate further the possible relationship between fallout radiation and leukemia 
among atomic veterans [8,9].
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Figure 1. 
Vital status through 2010 of SMOKY and PLUMBBOB nuclear weapons test participants. 
SMOKY is not included in the PLUMBBOB tabulations.
Caldwell et al. Page 13
J Radiol Prot. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Leukemia risk (other than CLL) over time for participants at the 1957 SMOKY test and 
PLUMBBOB series. 95% confidence limits are presented.
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